<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>RHPN1-AS1 RPS15A interaction &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/rhpn1-as1-rps15a-interaction/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 30 Sep 2025 08:19:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>RHPN1-AS1 RPS15A interaction &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>RHPN1-AS1 Drives Liver Cancer Progression Under Hypoxia</title>
		<link>https://bioengineer.org/rhpn1-as1-drives-liver-cancer-progression-under-hypoxia/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 30 Sep 2025 08:19:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[hypoxia in cancer]]></category>
		<category><![CDATA[long noncoding RNAs]]></category>
		<category><![CDATA[RHPN1-AS1 RPS15A interaction]]></category>
		<category><![CDATA[therapeutic targets in oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/rhpn1-as1-drives-liver-cancer-progression-under-hypoxia/</guid>

					<description><![CDATA[In the ever-evolving landscape of cancer research, the intricate mechanisms that drive tumor progression continue to captivate scientists seeking new therapeutic targets. Among the formidable challenges in oncology, hepatocellular carcinoma (HCC) stands out as one of the most lethal primary liver cancers worldwide, characterized by high mortality rates and limited treatment options. Recent breakthroughs have [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">273620</post-id>	</item>
	</channel>
</rss>
